Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

ILYM17047 / KTE-C19-105 (ZUMA-5) / Carla Casulo

Research Question:
For patients who have relapsed from or have refractory Indolent Non-Hodgkin Lymphoma, what is the disease response and safety when infused with the study treatment, axicabtagene ciloleucel?

Basic Study Information

Purpose:
This study will enroll approximately 160 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.

Location: University of Rochester Medical Center
Study Reference #: ILYM-17047

Lead Researcher (Principal Investigator)

Lead Researcher:  Carla Casulo

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search